Press Releases

17.06.2020
DGAP-Media

Aladdin Healthcare Technologies SE takes another big step forward in early diagnosis of Alzheimer´s Disease: Aladdin gets extensive multimodal data from the largest Dementia platform in the UK

  • Aladdin gains access to 4 important data cohorts that include key genetic data for dementia research
  • DPUK has three million dementia patients’ data through multiple cohorts
  • This data sets the stage for significant potential breakthroughs for new biomarkers for a new affordable non-invasive global test

BERLIN/LONDON, June 17, 2020 - Aladdin Healthcare Technologies SE (“Aladdin”, ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, gained approval by the Dementias Platform UK (DPUK) for accessing important biobanks containing a huge amount of medical data for dementia research. This data sets the stage for significant potential breakthroughs for new biomarkers for a novel affordable non-invasive global test that would create a new gold standard for Alzheimer’s testing and place Aladdin at the forefront of new generation diagnostic leaders.

Early this year, Aladdin applied for data access of important bio-databanks of the Dementias Platform UK. DPUK is a public-private partnership funded and led by the Medical Research Council (MRC) which aims to improve the early detection, treatment and prevention of dementia. The organisation is directed by Professor John Gallacher at the University of Oxford and involves several renowned academic and industry partners, such as the University of Cambridge, the King’s College in London and GlaxoSmithKline. The DPUK Data Portal provides researchers and companies with about 40 of UK’s existing population studies and with medical records of more than three million participants. Researchers can identify which data of cohort studies are relevant to them and apply for gaining access to the data. After approval, the multimodal data can be analysed and used for further healthcare findings.

Aladdin has recently gained approval for accessing the following cohort studies of DPUK, which are some of the richest data cohorts for dementia research: Whitehall II, BRACE, ELSA and Generation Scotland. This gives the Company the chance to improve its Artificial Intelligence (AI) assisted discovery process for early diagnosis of age-related neurodegenerative diseases. The new data can add significant new information to Aladdin’s proprietary Knowledge Graph and lead to more discoveries for new biomarkers.

Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies SE, comments: “Having access to some of DPUK´s data platforms enables us to build a multimodal approach for early stage non-invasive diagnosis, including genetic risk assessment. This would mark a new era for Alzheimer’s testing and place Aladdin at the forefront of new generation diagnostic leaders. The worldwide need for scaling up the research into neurodegenerative diseases like Dementia and Alzheimer´s is constantly increasing. Only through an integrated and targeted approach with multimodal data, we can reach a crucial breakthrough in the research for age-related diseases.”

Gaining access to these valuable biobanks is a further evidence of Aladdin’s ability to work with renowned international research partners. This represents the first step towards a bigger project of closing an official partnership and becoming a consortium member of the DPUK.

About Aladdin Healthcare Technologies SE

Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets aged related disease including a significant focus on Alzheimer’s disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including, genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose aged related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used to by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.

Website Link: www.aladdinid.com
GSIN: A12ULL
ISIN: DE000A12ULL2
TICKER SYMBOL: NMI

For further information
Aladdin Healthcare Technologies Ltd.
24-26 Baltic Street West
London EC1Y 0UR
Phone +44 7714 719696
Email: info@aladdinid.com

Contact Press
CROSS ALLIANCE communication GmbH
Susan Hoffmeister
Phone +49 89 1250 90330
Email: sh@crossalliance.de
www.crossalliance.de